Evaluation of effect of fluoxetine on the clinical prognosis in patients with Optic neuritis

Evaluation of effect of treatment by fluoxetine on clinical prognosis in patients with Optic neuritis in comparison between drug and placebo groups.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200719048138N1

Enrollment

100

Registered

2020-10-19

Start date

2019-10-04

Completion date

Unknown

Last updated

2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The Optic neuritis. Optic neuritis

Interventions

Intervention 1: Intervention group: Intervention group: receivers of fluoxetine antidepressant, 20 mg daily for 6 month. Intervention 2: Control group: Control group: Receivers of placebo of fluoxetin

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Iranian patients Age over 18 years old Patients diagnosed with Optic neuritis

Exclusion criteria

Exclusion criteria: History of multiple sclerosis cataract, glaucoma ( open or close angle ) congenital eye diseases such as coloboma and involvement with other disorders effecting the central visual field Patients with past medication history of using fluoxetine or other psychotherapeutics including antidepressants psychological disease medication history of arthemeter? astemizol, cisapride, eliglustat, goserelin, isocarboxazide, artemether, leuprolide, linezolid, lumefantrine, methylene blue, phenelzine, pimozide, procarbazine, selegiline, thioridazine, tranylcypromine Patients diagnosed with autoimmune and collagen vascular diseases Trauma or history of ophthalmologic surgeries Interval between involvement and interview more than 3 weeks Pregnancy

Design outcomes

Primary

Measure	Time frame
1)Visual acuity: precision of vision assessed by snelene chart. Timepoint: On first visit and 6th month after initiation of treatment. Method of measurement: Visual acuity: snelene chart.;VEP (Visual evoked potential) test: both time ( latency) and amplitude parameters of VEP test will measure. Timepoint: On first visit and 6th month after initiation of treatment. Method of measurement: VEP test by means of VEP device.	—

Measure

Time frame

1)Visual acuity: precision of vision assessed by snelene chart. Timepoint: On first visit and 6th month after initiation of treatment. Method of measurement: Visual acuity: snelene chart.;VEP (Visual evoked potential) test: both time ( latency) and amplitude parameters of VEP test will measure. Timepoint: On first visit and 6th month after initiation of treatment. Method of measurement: VEP test by means of VEP device.

—

Secondary

Measure	Time frame
OCT: thickness of retina. Timepoint: OCT: on first visit and 6th month after initiation of treatment. Method of measurement: OCT: OCT device.;Perimetry: percent of scotoma in visual field. Timepoint: Perimetry: On first visit and 6th month after initiation of treatment. Method of measurement: Perimetry: digital perimetry device.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Poormousa

Iran University of Medical Sciences

zpourmousa@yahoo.com+98 21 86709

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026